Drug Trial Radar · NCT01972568
Efficacy and Safety of Atacicept in Systemic Lupus Erythematosus
Last checked: Nov 20, 2026Latest source record: Jan 2, 2018 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
306
Actual
Start
Dec 2013
Primary completion
Apr 2016
Study completion Sep 2016
Sponsor
- Lead sponsor
- EMD SeronoIndustry
- Sponsor type
- Industry
- First posted
- Oct 30, 2013
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a multi-center, double-blind, randomized, Phase 2b trial to evaluate the efficacy of atacicept in subjects with systemic lupus erythematosus (SLE).
Conditions
- Lupus Erythematosus, Systemic
Interventions
Atacicept 75 milligram (mg)Drug
Atacicept 75 mg will be administered as subcutaneous injection once weekly for 24 weeks.
Atacicept 150 mgDrug
Atacicept 150 mg will be administered as subcutaneous injection once weekly for 24 weeks.
PlaceboDrug
Placebo matched to atacicept will be administered as subcutaneous injection once weekly for 24 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Subjects With Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response at Week 24 Using Screening Visit as BaselineTime frame: Week 24
- Percentage of Subjects With Systemic Lupus Erythematosus (SLE) Responder Index (SRI) Response at Week 24 Using Day 1 as BaselineTime frame: Week 24
Locations
138 sites in 18 countries. Site status is shown where the registry gives one.
Pinnacle Research Group LLC
Anniston, Alabama
Achieve Clinical Research, LLC
Birmingham, Alabama
University of Alabama at Birmingham - (UAB)
Birmingham, Alabama
Southern California Permanente Medical Group
Anaheim, California
Wallace Rheumatic Study Center
Los Angeles, California
East Bay Rheumatology Medical Group, Inc.
San Leandro, California
Clinical Research of West Florida - Corporate
Dunedin, Florida
Center for Rheumatology, Immunology & Arthritis
Fort Lauderdale, Florida
University of Miami Miller School of Medicine
Miami, Florida
Clinical Research of West Florida, Inc.
Tampa, Florida
Goldpoint Clinical Research, LLC
Indianapolis, Indiana
AA MRC LLC Ahmed Arif Medical Research Center
Grand Blanc, Michigan
Mayo Clinic
Rochester, Minnesota
North MS Medical Clinics, Inc.
Tupelo, Mississippi
Washington University School of Medicine
St Louis, Missouri
Rutgers New Jersey Medical School
Newark, New Jersey
The Feinstein Institute for Medical Research
Manhasset, New York
Hospital for Special Surgery
New York, New York
Box Arthritis & Rheumatology of the Carolinas PLLC
Charlotte, North Carolina
MetroHealth System
Cleveland, Ohio
Ohio State University Medical Center
Columbus, Ohio
STAT Research, Inc.
Dayton, Ohio
Arthritis & Rheumatology Center of Oklahoma
Oklahoma City, Oklahoma
OMRF
Oklahoma City, Oklahoma
Lynn Health Science Institute
Oklahoma City, Oklahoma
Clinical Research Center of Reading LLC
Wyomissing, Pennsylvania
Medical University of South Carolina (MUSC)
Charleston, South Carolina
UTMB Pathology Clinical Services
Galveston, Texas
Arthritis & Osteoporosis Clinic
Waco, Texas
Danville Orthopedic Clinic, Inc.
Danville, Virginia
APRILLUS
Ciudad Autonoma Buenos Aires, Argentina
Atencion Integral en Reumatologia (AIR)
Ciudad Autonoma Buenos Aires, Argentina
Hospital Italiano
Ciudad Autonoma Buenos Aires, Argentina
Organizacion Medica de Investigacion (OMI)
Ciudad Autonoma Buenos Aires, Argentina
Policlìnica Red Omip S.A - Ensayos Clinicos GC
Mar del Plata, Argentina
Centro de Investigacion Pergamino SA
Pergamino, Argentina
Cordis S.A.
Salta, Argentina
Centro Polivalente de Asistencia e Inv. Clinica CER
San Juan, Argentina
Centro Integral de Reumatologia
San Miguel de Tucumán, Argentina
Centro Medico Privado de Reumatologia
San Miguel de Tucumán, Argentina
Showing 40 of 138 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.